Two-step workflow taps cognitive screening before biomarker testing A new two-step approach to diagnosing Alzheimer’s disease (AD) in primary care shows promise for cutting false positives and streamlining referrals. Researchers tested a brief, self-administered digital cognitive battery, BioCog, first, and reserved amyloid-related blood tests for individuals who showed objective impairment. This “test-then-blood” workflow aims to…